The European treatment of severe atopic eczema in children taskforce (TREAT) survey
The European treatment of severe atopic eczema in children taskforce (TREAT) survey
复制标题
DOI：
10.1111/bjd.12505
复制
发表时间：
2013-10-01
影响因子：
10.3
通讯作者：
Flohr, C.
中科院分区：
文献类型：
--
作者：
Proudfoot, L. E.;Powell, A. M.;Flohr, C.
BackgroundThere is a few of evidence for use of systemic agents in children with atopic eczema refractory to conventional therapy，resulting in considerable variation in patient management.ObjectivesThe European TREatment of severe Atopic Eczema in children Taskforce（TREAT）survey was established to collect data on current prescribing practice，to identify factors affecting the use of specific systemic agents，并通知设计的临床相关的干预study.MethodsConsultant医生成员的儿科皮肤病学会和利益集团的8个欧洲国家被邀请参加一个基于网络的调查。多重应答格式的问卷整理数据的临床实践一般，以及使用全身性药物在难治性儿科特应性eczema.ResultsIn总的详细信息，343/765成员（44. 8%）回应邀请的电子邮件; 89. 2%的皮肤科医生和71%的严重特应性湿疹的儿童启动全身免疫抑制。首选一线药物为环孢素（43.0%）、口服糖皮质激素（30.7%）和硫唑嘌呤（21.7%）。环孢素也是最常用的二线药物（33.6%），甲氨蝶呤是最常用的第三选择（26.2%）。大约一半的受访者（53.7%）回答说，他们在开始全身治疗之前会常规检测和治疗皮肤感染的宿主。在这八个国家，青霉素是首选的一线抗生素（78.3%）。ConclusionsIn缺乏明确的证据基础，欧洲TREAT调查证实了广泛的变化，在处方实践中的全身免疫抑制难治性儿科特应性湿疹。研究结果将用于设计一项与欧洲患者管理相关的随机对照试验。
BackgroundThere is a paucity of evidence for the use of systemic agents in children with atopic eczema refractory to conventional therapy, resulting in considerable variation in patient management.ObjectivesThe European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey was established to collect data on current prescribing practice, to identify factors influencing the use of specific systemic agents, and to inform the design of a clinically relevant intervention study.MethodsConsultant physician members of the paediatric dermatology societies and interest groups of eight European countries were invited to participate in a web-based survey. The multiple-response format questionnaire collated data on clinical practice in general, as well as detailed information on the use of systemic agents in refractory paediatric atopic eczema.ResultsIn total, 343/765 members (44.8%) responded to the invitational emails; 89.2% were dermatologists and 71% initiate systemic immunosuppression for children with severe atopic eczema. The first-line drugs of choice were ciclosporin (43.0%), oral corticosteroids (30.7%) and azathioprine (21.7%). Ciclosporin was also the most commonly used second-line medication (33.6%), with methotrexate ranked as most popular third choice (26.2%). Around half of the respondents (53.7%) replied that they routinely test and treat reservoirs of cutaneous infection prior to starting systemic treatment. Across the eight countries, penicillins were the first-line antibiotic of choice (78.3%).ConclusionsIn the absence of a clear evidence base, the European TREAT survey confirms the wide variation in prescribing practice of systemic immunosuppression in refractory paediatric atopic eczema. The results will be used to inform the design of a randomized controlled trial relevant to patient management across Europe.